Sign in to fuzzto save your conversations, follow your research and come back anytime.
Wockhardt
SectorHealthcare
In the news
Wockhardt Stock Delivers 776% Returns in 3 Years
Wockhardt shares surge 7% for fifth straight session
Wockhardt targets Q1 2027 US launch for breakthrough antibiotic
Wockhardt posts ₹107 cr Q1 profit vs ₹108 cr loss last year
India's Pharma Renaissance: From Generics to Drug Discovery
Wockhardt's Zaynich becomes India's first FDA-approved antibiotic
Experts advise hold on IDFC First Bank, JSW Energy stocks
Wockhardt drops fifth straight session, down 0.67%
Wockhardt shares surge 2.19% for third straight session
Wockhardt targets 50% revenue from novel drugs within five years
Wockhardt's Zaynich becomes India's second US FDA-approved antibiotic
Wockhardt shares fall 8% after historic Zaynich approval rally
Sensex falls 293 pts; Nifty drops 57 pts amid broad selloff
Wockhardt shares hit record ₹2,420 after US FDA approves Zaynich antibiotic
Wockhardt's Zaynich: A Historic Breakthrough in Antibiotic Innovation
5 Low-Risk Pharma Stocks for 2026: Healthcare Screener Analysis
Wockhardt hits all-time high at ₹2,092 on CDSCO antibiotic approval
Wockhardt shares surge 8.35% for fifth straight session on US FDA approval
Wockhardt's Zaynich gets US FDA approval, first Indian NCE milestone
Wockhardt stock zooms 14% on historic US FDA approval for ZAYNICH
Company insights, generated from the most recent coverage.
Down ~14.5% from the ₹2,360 peak hit on Sep 23, 2026, with the stock off ~3% intraday on Oct 5 and -11.8% over one week — a post-rally profit-booking correction with no fresh company-specific negative trigger.
The planned ₹3,000 Cr capital markets raise announced in July 2026 (also an Aug 10 AGM agenda item) is a persistent dilution overhang — EPS for existing shareholders gets compressed, and until structure and pricing are clarified it caps upside in the stock.
Price has slipped below the 50-EMA while still holding above the 200-EMA — short-term momentum has broken but the long-term uptrend is intact. The ₹2,010–2,050 zone is the pivot; a close below ₹2,010 risks accelerating downside, with ₹2,125 as overhead resistance.